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Abstract A new bilayer-coated microbeads for oral delivery of 5-aminosalicylic
acid (5-ASA) were prepared from naturally occurring polysaccharides via emulsi-
fication method. 5-ASA was successfully encapsulated in chitosan–k-carrageenan-
coated alginate microbeads. The morphology and sizes of microparticles were
studied using optical microscopy and dynamic light scattering. Drug release profiles
were followed using high-performance liquid chromatography (HPLC) with spec-
trophotometric detection. The effect of chitosan thin layer and chitosan–k-carra-
geenan bilayer on the drug release was studied at pH values simulating these
characteristic for stomach (pH = 1.2) and intestine (pH = 7.4). Chitosan layer
slightly increased 5-ASA release at pH = 1.2, whereas double-layer external
coating decreased the release rates. Due to the bilayer properties, the micro-carriers
were additionally protected against acidic conditions of the stomach and drug
release in the intestine could be better controlled.
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Introduction
5-Aminosalicylic acid (5-ASA) has been successfully used for over a decade in the
treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis or
Crohn’s disease. Patients suffering from these maladies are exposed to increased
risk for the development of colorectal cancer (CRC) and the risk becomes higher
with the extent and duration of the disease. Experimental and epidemiological
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studies suggest that long-term regular intake of 5-ASA may reduce the occurrence
of colorectal cancer in patients with IBD. Bernstein et al. [1] have studied the effect
of various chemical agents on CRC chemoprevention and demonstrated the strong
protective association of regular 5-ASA therapy reducing cancer risk by 81%. These
findings were followed by intense studies on mechanism of action explaining
therapeutic effect of 5-ASA on CRC prevention. Several articles have been
published showing that 5-ASA reduces significantly the growth and survival of CRC
cells [2–4].
An important factor in the successful prevention of colorectal cancer is patient’s
compliance. Strong adverse effects (hepatitis, blood dyscrasias, pancreatitis, or
interstitial nephritis) associated with oral 5-ASA therapy [5] as well as a need of
regular long-term treatment make patient’s compliance difficult to achieve.
Decreasing the 5-ASA dose and frequency of intake and developing the optimal
matrix for decreasing adverse effects would, therefore, be of great importance.
When administered orally, 5-aminosalicylic acid should be delivered in the form
allowing reduction of its systemic absorption and degradation while drug is passing
the stomach. 5-ASA is known to be rapidly absorbed from small intestine, so a
sufficient protection in this part of the gastrointestinal tract is also necessary to
assure optimal delivery of the active moiety to the colon. Lakatos et al. [6] have
reported that one-daily formulation of 5-ASA, delayed-release tablets of mesalazine
utilizing Multi-Matrix System (MMX) technology, has been recently approved in
the US for the induction and maintenance of remission in patients with active
ulcerative colitis. However, the total systemic absorption of the new drug does not
show any supremacy over the other 5-ASA formulations.
Naturally occurring polysaccharides, such as alginate, k-carrageenan, or chitosan,
are widely used in drug delivery due to their biocompatibility, mucoadhesive
properties, abundance in nature and low cost. Sodium alginate is well known for its
ability to form pH-sensitive hydrogels under mild conditions upon addition of
calcium ions. Its swelling in acidic conditions typical for stomach (pH = 1.2) is
minimal, assuring good protection of the compound embedded in the gel structure.
However, considering the practical applications, one should ensure that the extent of
swelling can be also controlled at higher pH, characteristic for the small intestine
and colon, where alginate gels swell considerably. We suggest that this can be
achieved by coating of alginate matrix with chitosan, natural polymer whose
solubility at pH higher than 6.5 is considerably limited. The presence of chitosan
should suppress the microsphere erosion in small intestine and colon leading to
significant decrease and better control over 5-aminosalicylic acid release.
Both polymers, as well as their combination, have been already applied to obtain
microbeads [7]. Also, multilayer systems composed of both polysaccharides were
applied successfully to deliver drugs (e.g. ampicillin) [8]. There are, however, very
few articles on controlled delivery of 5-ASA using microspherical systems.
Moreover, in those systems the commercially available enteric coating materials
(such as Eudragit or Aquacoat) are applied as single outer layer to protect the drug
while passing of the stomach [9].
Here we propose alginate–chitosan–k-carrageenan microparticulate system for
controlled delivery of 5-ASA based on ultrathin double-layered external coating of
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the alginate matrix. While the internal chitosan layer should decrease drug’s release
in jejunum and the ileum of the gut, the main role of the outer layer would be to
protect the internal layer from the dissolution in the stomach. Our choice was to use
k-carrageenan. Carrageenans are polysaccharides extracted from red seaweeds and
widely used in food and pharmaceutical industry. There are three main classes of
carrageenans: kappa, iota, and lambda, differing in the number and position of the
ester sulfate groups on the repeating galactose units. In our studies k-carrageenan
was chosen due to the highest level of ester sulfate. This property provides good
water solubility and high charge density of the polymer chain. In our procedure, first
the Ca-alginate microbeads containing 5-ASA were produced and then they were
coated with the external thin layers (chitosan followed by k-carrageenan). This
allowed for studying the effect of the inner and outer layer on the release profiles in
pH simulating body fluids (stomach and intestine). Considering the fact that the
relative amounts of chitosan and k-carrageenan present in the microparticles are
extremely low, the bulk properties of the alginate gel matrix are not modified.
Experimental
Materials
5-Aminosalicylic acid (Sigma, purity *99%), alginic acid sodium salt from brown
algae (sodium alginate, Sigma, viscosity of the 2% solution at 25 C: *2,000 cP),
chitosan (Aldrich, low molecular weight, 75–85% deacetylated, viscosity of 1%
solution in 1% acetic acid at at 25 C: 20–200 cP,), k-carrageenan (BioChemika
(Sigma)), calcium chloride (Sigma-Aldrich, min. 93%, granular, anhydrous),
methanol for chromatographic measurements (Fluka, for HPLC, gradient grade,
C99.8% (GC)), ethylenediaminetetraacetic acid tetrasodium salt hydrate (EDTA,
SigmaUltra, C99% (KT)), distilled water was of MilliQ grade.
Preparation of uncoated microbeads
5-ASA-loaded alginate microparticles were prepared by emulsification method
using calcium chloride as a crosslinking agent. 2.808 g of stabilizing agent (Tween
85) was added to 160 ml of cyclohexane and stirred until completely dissolved.
Then, aqueous solution containing 0.4 g (1.25 wt%) of sodium alginate and 100 mg
(2.2 mM) of 5-ASA was added dropwise. The mixture was then stirred at 800 rpm
for about 10 min to obtain stable emulsion. Next, 30 ml of 0.2 M aqueous solution
of calcium chloride was added dropwise to the reaction mixture to obtain
crosslinked alginate microparticles encapsulating 5-ASA molecules in the calcium
alginate matrix. Emulsion was then stirred for another 30 min. After this time,
stirring was switched off and emulsion was left for 1 h to allow microspheres to
harden. The microparticles thus formed were then filtered and washed with distilled
water and 2-propanol.
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Coating procedure
5-ASA-loaded microbeads were coated with thin layers of chitosan and
k-carrageenan. For this purpose, the solutions of chitosan and k-carrageenan were
prepared in 0.02 M acetic acid with addition of NaCl (0.15 M) to assure invariability
of the ionic strength. pH of both solutions was adjusted to 5.0 and then they were
filtered up by using syringe filter (pore size: 0.45 lm). To obtain each layer, the
microspheres were introduced to the solution of the polyelectrolyte and mixed for
about 30 min. Then, they were filtered up and washed with distilled water.
Optical microscopy measurements
Optical microscope imaging was performed using Nikon Eclipse TE2000 Inverted
Research Microscope System. All the images were obtained in the air using Plan
Achromat 50x objective. A small amount of the sample studied (ca 2 mg) was
dispersed in water using ultrasonic bath and spread over the glass slide directly
before the measurement. The diameter of the microbeads was measured as a mean
value for 100 microbeads.
SEM measurements
Field-emission scanning electron microscopy (FE-SEM, Hitachi S-4700) equipped
with energy dispersive X-ray spectroscope (EDS) was used to study the morphology
and microstructure of microbeads (magnifications from 5,0009 to 20,0009).
Sample was dispersed and diluted in water, spread over the thin glass slide and dried
in the stream of gaseous nitrogen directly prior to measurement.
Encapsulation efficiency measurements
Encapsulation efficiency was measured by dissolving the precisely weighted sample
of the microspheres in 5 mM EDTA solution containing NaCl (100 mM) at
pH = 7.4. The sample was then stirred at room temperature until the microparticles
were completely dissolved. 1 ml of the resulting solution was then tested using
HPLC method in order to measure the concentration of 5-ASA. Before each
measurement a calibration curve was obtained for 10 standard solutions of
5-aminosalicylic acid. Encapsulation efficiency (EE) was calculated from the
following equation:
EE ¼ Wenc=Wintð Þ  100% ð1Þ
where Wenc amount of 5-ASA encapsulated in macrospheres, Wint amount of 5-ASA
in the reaction mixture
DLS measurements
The light scattering measurements were performed using Malvern Instruments
ZETASIZER NANO-ZS. The samples were prepared in aqueous solution, filtered
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through Chromafil filter (0.45 lm) and measured at room temperature. Data were
analyzed using the Malvern software and were the average from six measurements.
All the experiments were performed in triplicate.
Release studies
To study the release of 5-ASA from the microspheres, the 15 mg samples were
placed in 7 ml plastic centrifuge tubes and 3 ml of the medium solution was added.
A 0.1 M solution of HCl was used to simulate the pH of the stomach while PBS
solution (pH = 6.8) was used to simulate the intestine pH. Each sample was then
left in the water bath at 37 C, while constantly stirred. After defined period of time,
the tube with the sample was centrifuged and all the solution withdrawn. The
solution was then analyzed to determine the drug concentration. Then, a new portion
of the release medium (3 mL) was added to the microsphere sample and the release
studies were continued.
Drug concentration measurements were done using HPLC method. The analysis
was performed using C18 RP column and UV/Vis spectrophotometric detection
at 317 nm. Water/citric buffer (10 mM; pH = 2.75)/acetonitrile/methanol were
mixed in proportion: 13:1:3:3 (v/v/v/v) and the obtained solution was used as a
mobile phase. The flow rate was 0.5 mL/min. All the samples were measured in
triplicate.
Results
The microbeads prepared using emulsification method were characterized using the
optical microscopy to determine their morphology and size distribution. As can be
seen at the images presented in Fig. 1a and b, the spherical objects of micrometric
size (2–10 lm) were obtained, although in some cases small morphological
irregularities could be also observed. This can be explained considering soft and
rather fragile nature of the hydrogel structure of Ca-alginate particles The
microspheres show a moderate tendency for aggregation. Incorporation of 5-ASA
into microspheres influences their morphology significantly (Fig. 1c, d). 5-ASA
encapsulating microparticles show well-defined spherical shape, but they have
higher size dispersion. The average bead diameter was estimated to be 9.2 lm.
5-ASA encapsulation efficiency was 20%.
Those observations were confirmed by using Scanning Electron Microscopy.
SEM images (Fig. 2a–c) show symmetrical spherical objects of the smooth surface
and the size of ca 2–3 lm. To obtain such images the particles had to be sufficiently
hydrated. Upon high pressures in the SEM apparatus fast dehydration occurred,
followed by the microsphere subsidence due to the collapse of the hydrogel
structure (Fig. 2d).
To increase the control over the drug release from the particles, two additional
thin polysaccharide layers were introduced; first a chitosan and then k-carrageenan
layer. For this purpose, the electrostatic self assembly technique, known also as a
layer-by-layer method [10, 11], was used. To verify the presence of the coating, zeta
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potential measurements were performed, after the microparticles were coated with
each layer (chitosan and then k-carrageenan; see Table 1). As expected, in the
neutral pH uncoated microbeads show negative surface charge due to the presence
of ionized carboxylic groups of the alginate matrix, whereas in the acidic media the
ionization is suppressed and zeta potential values are close to zero. In acidic
chitosan solution the polymeric chains are positively charged and zeta potential of
chitosan-coated microspheres is low, but positive. At pH = 6.8, zeta potential of
chitosan-coated microparticles is still negative, but its absolute value is lower than
that for uncoated microparticles.
Introduction of the outer carrageenan layer decreases zeta potential. Carrageenan
sulfonate groups are ionized regardless of the pH. The observed difference results
from the compensation of alginate–chitosan charges. The fact that both layers have
limited effect on the zeta potential of the microspheres can be explained by the fact
that both of them are very thin and taking into account the fact that polymeric chains
of the polysaccharides used to form the layer can easily interpenetrate the outer part
of the microbead.
Release profiles were obtained for two different pH values: 1.2 and 6.8, typical
for stomach and intestine environment, respectively. 5-ASA concentration was
Fig. 1 Optical microscope images of uncoated alginate microparticles obtained for: a non-loaded
particles (950 magnification), b non-loaded particles (9100), c 5-ASA-loaded particles (950), and d of
alginate microparticles obtained for chitosan/carragenan bilayer-coated, 5-ASA-loaded particles (9100)
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measured using HPLC method. Calibration curve for ten standards was done prior to
each measurement series and each time excellent fit was obtained (R2 C 0.99).
The release of 5-ASA from the obtained microspheres is very effective in the first
2 h. Only 10% or less is retained after this time and then the release slows down
significantly. As can be seen in Fig. 3b, in the stomach-like environment (pH = 1.2)
in the first 2 h chitosan coating has only slight accelerating effect on the release of
5-ASA in comparison to the release from the uncoated microbeads. For the longer
release times, the profiles (Fig. 3a) are identical for both the types of microparticles
Fig. 2 SEM images of 5-ASA-loaded, uncoated alginate microparticles: a 95,000 magnification—two
non-aggregated wet microparticles; b 920,000 magnification—two aggregated wet particles of spherical
shape and smooth surface; c 918,000 magnification—single wet particle of highly spherical shape
(reflections due to the wetness), d 920,000 magnification—single dry particle with uneven surface and
irregular shape due to the water loss of the hydrogel matrix
Table 1 Zeta potential (f) for
uncoated and coated alginate
microbeads
Coating type Zeta potential
at pH = 1.2
Zeta potential
at pH = 6.8
None -4.5 ± 1.7 -34.2 ± 1.7
Chitosan 0.5 ± 2.2 -29.7 ± 2.1
Chitosan and carrageenan -1.1 ± 1.6 -30.5 ± 1.2
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suggesting complete dissolution of the outer layer. Introduction of the chitosan–
carrageenan bilayer, however, slows down the release process considerably (by ca
40% in the first 2 h). Slow release can be observed even after 2 days, confirming
that the bilayer is relatively stable in acidic media. After 3 days practically all
5-ASA is released, most probably due to the matrix degradation process.
Figure 4 shows the release profile at the pH = 6.8, simulating that of the human
intestine. The presence of chitosan layer accelerates slightly the drug release in the
first 2 h. The chitosan–carrageenan double-layer coating, however, significantly
slows down the drug release under the intestinal-like pH (pH = 6.8). 5-ASA is still
released from those microspheres even after 2 days.
Figure 5 shows the differences in the release profiles of 5-ASA from the bilayer-
coated microparticles in various pH. For the first 90 min the release is slower in the
acidic medium and then the tendency is reversed. After 100 h the profiles intercross
again but at this stage almost all the drug is already released in both media.
Discussion
As one can expect, the additional thin layers of chitosan and carrageenan deposited
on microbeads do not modify their morphology, as observed using optical
microscopy. However, the substantial differences in the drug release profiles from
the uncoated and coated particles are observed, suggesting that the significant
modification of the microparticles’ surface has occurred.
Increase in the release rate of 5-ASA from chitosan-coated beads in pH = 1.2
may be explained taking into account the possibility of partial dissolution of the
chitosan layer in acidic media, inducing some morphological changes in the alginate
matrix. The similar release profiles for chitosan-coated and uncoated microspheres
at that pH can be caused by the complete dissolution of the outer layer. In the
environment of intestine the chitosan layer is more compact and cannot be easily
penetrated by water. As a result, it slows down the drug release. After 2 h the
release profiles for uncoated and chitosan-coated beads become almost identical.
Fig. 3 Release profiles for uncoated and coated microspheres at pH = 1.2; a full profiles, b profiles for
the first 6 h; uncoated (filled circle), chitosan-coated (open square) and chitosan–k-carrageenan-coated
(open diamond) microbeads
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Again that may be explained considering the interpenetration of the chitosan chain
into alginate matrix and possibility of slow degradation of the thin chitosan layer
with the time.
Upon addition of the second layer, the release rate decreases in both
environments. The profiles for double-layer-coated beads show that at the beginning
more drug is released at pH = 6.8 and after 90 min the inversion of the tendency is
observed. Since it has been estimated that it takes ca 2 h for the 5-ASA carriers to
pass the stomach after their administration, this tendency appears to be
advantageous.
To characterize the release mechanisms, the Higuchi [12] and Peppas [13] kinetic
models are widely used. Both models, however, are short time approximations and
their use is limited to the first 60% of the release. The Weibull model, on the other
hand, is an alternative empirical equation that can be used to describe the entire set
of experimental data. Although its parameters do not have direct physical
interpretation, Papadopoulou and coworkers [14] in their work provided a link
between the values of b and the mechanism of the release. The Weibull model fits to
the experimental profiles obtained for uncoated and coated microspheres are
presented in Table 2.
Fig. 4 Release profiles for uncoated and coated microspheres at pH = 6.8; a full profiles, b profiles for
the first 6 h; uncoated (filled circle), chitosan-coated (open square) and chitosan–k-carrageenan-coated
(open diamond) microbeads
Fig. 5 Release profiles of bilayer-coated microbeads in pH characteristic for stomach (filled circle) and
intestine (open diamond); a full profiles, b profiles for the first 6 h
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For the majority of the samples, the calculated b values were above 1. This is
indicative of complex release mechanism. There are, however, two exceptions. The
release from the chitosan-coated particles in acidic medium can be associated with
drug diffusion in normal Euclidian space (b = 0.7) [15]. The lowest b value was
obtained for the bilayer-coated microspheres in pH = 6.8 (b = 0.42) and according
to Kosmidis et al. [15] in this case the release can be described by the diffusion
mechanism in fractal or disordered substrate.
Conclusions
We have obtained the new ultrathin bilayer-coated micro-carriers for controlled oral
delivery of 5-aminosalicylic acid from the safe, biodegradable, and easily available
polysaccharides. 5-ASA was efficiently encapsulated in the synthesized micro-
spheres. The particles are spherical with smooth surface and sizes in the range of
several micrometers, as confirmed by optical microscopy and SEM measurements.
The effect of the chitosan layer and bilayer coating on the release profiles of 5-ASA
was studied at pH characteristic for stomach and intestine. Both the thin layers
influence the release profile significantly. Chitosan/carrageenan coating slows down
the release of 5-ASA considerably at both pH. The release profile suggests that the
process is a two-stage phenomenon. After the first 2 h (fast delivery), the slow
sustained release is observed up to 8 h. 5-ASA-containing alginate micro-carriers
gained the additional protection against acidic conditions of stomach and the drug
release in the intestine can be better controlled. The Weibull model was fitted to all
experimentally obtained profiles and the possible mechanism of 5-ASA release
kinetics was discussed.
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Table 2 Parameters and
coefficients obtained for Weibull
release kinetic model fitted to
the experimental 5-ASA release
profiles at pH characteristic for
stomach (pH = 1.2) and
intestine (pH = 6.8)












a 99.0 ± 0.44 99.1 ± 0.32 97.4 ± 0.96
b 1.2 ± 0.15 0.70 ± 0.097 1.7 ± 0.20
K 1.38 ± 0.074 2.8 ± 0.43 0.84 ± 0.030
R2 0.9872 0.9816 0.9858
pH = 6.8
a 97.9 ± 0.61 98.4 ± 0.47 970 ± 1.8
b 1.4 ± 0.20 1.5 ± 0.13 0.42 ± 0.089
K 1.19 ± 0.053 1.03 ± 0.023 1.3 ± 0.30
R2 0.9834 0.9936 0.9930
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